219 related articles for article (PubMed ID: 17671645)
1. Retroviral integration and human gene therapy.
Bushman FD
J Clin Invest; 2007 Aug; 117(8):2083-6. PubMed ID: 17671645
[TBL] [Abstract][Full Text] [Related]
2. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.
Deichmann A; Hacein-Bey-Abina S; Schmidt M; Garrigue A; Brugman MH; Hu J; Glimm H; Gyapay G; Prum B; Fraser CC; Fischer N; Schwarzwaelder K; Siegler ML; de Ridder D; Pike-Overzet K; Howe SJ; Thrasher AJ; Wagemaker G; Abel U; Staal FJ; Delabesse E; Villeval JL; Aronow B; Hue C; Prinz C; Wissler M; Klanke C; Weissenbach J; Alexander I; Fischer A; von Kalle C; Cavazzana-Calvo M
J Clin Invest; 2007 Aug; 117(8):2225-32. PubMed ID: 17671652
[TBL] [Abstract][Full Text] [Related]
3. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.
Schwarzwaelder K; Howe SJ; Schmidt M; Brugman MH; Deichmann A; Glimm H; Schmidt S; Prinz C; Wissler M; King DJ; Zhang F; Parsley KL; Gilmour KC; Sinclair J; Bayford J; Peraj R; Pike-Overzet K; Staal FJ; de Ridder D; Kinnon C; Abel U; Wagemaker G; Gaspar HB; Thrasher AJ; von Kalle C
J Clin Invest; 2007 Aug; 117(8):2241-9. PubMed ID: 17671654
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
5. Hot spots of retroviral integration in human CD34+ hematopoietic cells.
Cattoglio C; Facchini G; Sartori D; Antonelli A; Miccio A; Cassani B; Schmidt M; von Kalle C; Howe S; Thrasher AJ; Aiuti A; Ferrari G; Recchia A; Mavilio F
Blood; 2007 Sep; 110(6):1770-8. PubMed ID: 17507662
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
7. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
8. Retroviral integration sites correlate with expressed genes in hematopoietic stem cells.
Wagner W; Laufs S; Blake J; Schwager C; Wu X; Zeller JW; Ho AD; Fruehauf S
Stem Cells; 2005 Sep; 23(8):1050-8. PubMed ID: 16140869
[TBL] [Abstract][Full Text] [Related]
9. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
[TBL] [Abstract][Full Text] [Related]
10. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
[TBL] [Abstract][Full Text] [Related]
11. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
[TBL] [Abstract][Full Text] [Related]
12. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.
Papayannakos C; Daniel R
Gene Ther; 2013 Jun; 20(6):581-8. PubMed ID: 23171920
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy fulfilling its promise.
Kohn DB; Candotti F
N Engl J Med; 2009 Jan; 360(5):518-21. PubMed ID: 19179320
[No Abstract] [Full Text] [Related]
14. Comparison of five retrovirus vectors containing the human IL-2 receptor gamma chain gene for their ability to restore T and B lymphocytes in the X-linked severe combined immunodeficiency mouse model.
Avilés Mendoza GJ; Seidel NE; Otsu M; Anderson SM; Simon-Stoos K; Herrera A; Hoogstraten-Miller S; Malech HL; Candotti F; Puck JM; Bodine DM
Mol Ther; 2001 Apr; 3(4):565-73. PubMed ID: 11319919
[TBL] [Abstract][Full Text] [Related]
15. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
16. Stem cell gene transfer: insights into integration and hematopoiesis from primate genetic marking studies.
Dunbar CE
Ann N Y Acad Sci; 2005 Jun; 1044():178-82. PubMed ID: 15958711
[TBL] [Abstract][Full Text] [Related]
17. The evolution of gene therapy in X-linked severe combined immunodeficiency.
Rans TS; England R
Ann Allergy Asthma Immunol; 2009 May; 102(5):357-62; quiz 363-5, 402. PubMed ID: 19492655
[TBL] [Abstract][Full Text] [Related]
18. Integrating Vectors for Gene Therapy and Clonal Tracking of Engineered Hematopoiesis.
Biasco L; Rothe M; Schott JW; Schambach A
Hematol Oncol Clin North Am; 2017 Oct; 31(5):737-752. PubMed ID: 28895844
[TBL] [Abstract][Full Text] [Related]
19. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
20. Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.
Hai M; Adler RL; Bauer TR; Tuschong LM; Gu YC; Wu X; Hickstein DD
Gene Ther; 2008 Jul; 15(14):1067-71. PubMed ID: 18369320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]